



**FOR IMMEDIATE RELEASE!**

**June 1, 2006**

**CONTACT:** Michael K. Lester  
Chief Executive Officer  
RADIANT RESEARCH  
(425) 468-6200

Pamela M. Spaniac  
Chief Operating Officer  
RADIANT RESEARCH  
(425) 468-6200

## **Radiant Research Completes Sale of Clinical Pharmacology Business Unit**

---

### ***Will Continue to Expand Clinical Research and Development Services***

**BELLEVUE, Wash.** – Radiant Research, a comprehensive clinical research company, today announced that it has completed the sale of its Early Phase Clinical Research Business Unit which included eight clinical pharmacology centers to Covance Inc. for approximately \$65 million.

Both companies had previously announced entering into a definitive agreement on April 20, 2006.

Radiant Research provides study conduct and drug development services to the biopharmaceutical industry. The eight centers acquired by Covance specialized in Phase I/IIa clinical pharmacology trials. Radiant's remaining 30 wholly-owned centers conduct trials in Phases IIb-IV.

Radiant's clients and study participants can expect our Phase IIb-IV study conduct services to continue as usual. "Conducting clinical trials is our core business", said Michael Lester, Chief Executive Officer of Radiant Research. "We focus on clinical research execution everyday."

"Radiant Research maintains a proprietary database of more than one million study participants. Our goal is to align all of our assets which include our participant recruitment, quality and training programs in addition to our standardized operating procedures and centralized source documentation for rapid, turn-key study start up," said Lester. "Drug development is an extremely complex business, and we are focusing on being industry leaders in the delivery of clinical research and development services."

"We enjoyed a record year in 2005," added Pamela Spaniac, Chief Operating Officer of Radiant Research. "Our senior management team is committed to continued growth and delivering professional, high quality clinical research and development services across the United States."

"By assembling a group of the country's leading clinical investigators in a unified organization, we are raising the standards of clinical studies. Human clinical trials represent two-thirds of the cost and over half of the time involved in bringing a drug to market. Radiant's unique combination of its wholly-owned centers, centralized processes and quality management programs save study sponsors a significant amount of time and money in the critical early stages of study

implementation. Our track record is one of rapidly achieving recruitment goals, so studies have a smooth start and completion rate, while collecting high quality clinical data needed to support the safety and efficacy of the sponsor's drug to the FDA," said Spaniac.

**About Radiant Research:**

Based near Seattle, Washington, Radiant Research ([radiantresearch.com](http://radiantresearch.com)) is a comprehensive clinical research and development company serving the biopharmaceutical and medical device industry. Radiant is comprised of more than 30 wholly-owned premier clinical research centers nationwide, employing over 500 clinical research professionals exclusively focused on providing professional, high quality study conduct and drug development services. In the past four years, Radiant has conducted more than 8,000 clinical trials across 18 therapeutic specialties.

**###**